

Supplementary Information to:

Mass spectrometry-based *de novo* sequencing of the anti-FLAG-M2 antibody using multiple proteases and a dual fragmentation scheme

Authors:

Weiwei Peng^{1#}, Matti F. Pronker^{1#}, Joost Snijder^{1*}

#equal contribution

*corresponding author: j.snijder@uu.nl

Affiliation:

¹ Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands

Keywords:

mass spectrometry, antibody, *de novo* sequencing, EThcD, stepped HCD, Herceptin, FLAG tag, anti-FLAG-M2.

anti-FLAG-M2 MS-based sequence (with L51I correction)

>anti-FLAG-M2_MS_HeavyChain

QVQLQQSAAELARPGASVKMSCKASGYSFTTYTIHWVKQRPGGLEWIGYINPSSGYAAYNQNFKDETTLTADPSSS
TAYMELNSLTSEDSAVYYCAREKFYGYDYWGQATLTVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPV
TVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSPRPSETVTCNVAHPASSTKVDDKIVPRDCGCKPCICTVPEV
SSVFIFPPKPKDVLITITLTPKVTCVWVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWL
NGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENY
KNTQPIMNTNGSYFVYSKLVNQKSNWEAGNTFTCSVLHEGLHNHHTKSLSHSPGK

>anti-FLAG-M2_MS_LightChain

DVLMTQIPLSLPVSLGDQASISCRSSQSIVHRNGNTYLEWYLLKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFT
LKISRVEAEDLGVYYCFQGSHPYTFGGGTKLEIRRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWK
IDGSERQNGVLNSWTDQDSKDYSTYSMSSTLTTLTKDEYERHNSYTCEATHKSTSTSPIVKSFNREK

Table S1. Coverage statistics for the Herceptin benchmark and anti-FLAG™-M2 MAb sequences.

		Herceptin	anti-FLAG-M2
# peptide reads (Byonic score >=500)	total	4408	3371
	stepped HCD	2686	1983
	EThcD	1722	1388
total		148 [8-394]	84 [0-382]
depth-of-coverage (median [range])	CDRH1	163 [158-176]	32 [22-47]
	CDRH2	94 [88-103]	39 [36-43]
	CDRH3	42 [18-67]	66 [50-75]
	CDRL1	210 [208-218]	192 [144-207]
	CDRL2	74 [71-84]	46 [40-60]
	CDRL3	140 [130-143]	127 [109-131]

Table S2. Model statistics for Fab crystal structure.


Refinement statistics		
Resolution (Å)	42.52-1.86	
No. of reflections	39988	
PDB	2G60 (old)	7BG1 (new)
Total number of atoms	3518	3497
Average atomic displacement parameter (Å ²)	45.0	52.0
$R_{\text{work}}/R_{\text{free}}$	0.235/0.278	0.217/0.255
Bond length RMSZ	0.93	0.28
Bond angle RMSZ	0.96	0.51
Ramachandran favored/outliers (%)	93.0/1.0	97.57/0.24
Molprobit score	3.37	1.60
Clashscore	56	3.61

Table S3. Comparison of CDR sequences from anti-FLAG™-M2 to other known FLAG™-tag binding MAbs (see refs 36-37).

Heavy Chain			
MAb	CDRH1	CDRH2	CDRH3
anti-FLAG-M2	GYSFTTYT----	LNPSSGYA	AREKFYGYDY
2H8	GFSLNTSGRS--	IYWDDDK	ARRMDY
EEh13.6	GDSLSSFNAGVN	HGAVM-STR	AKSTGRYDF
EEh14.3	GDSLSSYNAGVN	HMAGV-STR	VRNEWSGAF
EEf15.4	GFSIK--GANVN	HVRGDASTR	ADRMYSFYSGGEA

Light Chain			
MAb	CDRL1	CDRL2	CDRL3
anti-FLAG-M2	QSIVHRNGNTY	KVS	FQGSHVPYT
2H8	QSLVHSNGNTY	KVS	SQSTHVPYT
EEh13.6	QSIVHSNGNTY	KVS	FQGS LVPPT
EEh14.3	QSIVHSNGNTY	KVS	FQGS LVPPT
EEf15.4	NARSGS	DGN	SAFDQTNKYVG

A) Herceptin



A) anti-FLAG-M2




Figure S1. Coverage maps of Herceptin benchmark (A) and anti-FLAG™-M2 MAb (B) sequences. Peptides with Byonic scores of ≥ 500 are shown.




Figure S2. Depth of coverage profiles for Herceptin (A) and anti-FLAG™-M2 (B) sequences, based on peptides with Byonic score ≥ 500 , as in Figure S1.




Figure S3. Isoleucine/Leucine assignment at Heavy Chain position 51 of anti-FLAG™-M2. (left panel) Electron density around isoleucine 51 at a contour level of 1.0 RMSD in blue and simulated annealing omit map density of the C_{γ1}, C_{γ2} and C_δ atoms of this residue at a contour level of 2.5 R.M.S.D. in green. (right panel) A leucine instead of an isoleucine in this location has a poor fit to both maps.




Figure S4. Electrostatic surface potential of the anti-FLAGTM-M2 paratope. The revised crystal structure based on the MS-derived sequence (PDB ID: 7BG1) is shown alongside the original model (PDB ID: 2G60). The electrostatic surface was calculated with the default *coulombic* command in ChimeraX.




Figure S5. Western blot validation of synthetic recombinant anti-FLAG™-M2 compared to the originally sequenced sample. Same Western blot as shown in Figure 3C, showing complete lanes with marker positions.